<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>PB-718: what changed | Grey Peptides</title>
    <link>https://greypeptides.com/changes/#e-pb-718</link>
    <atom:link href="https://greypeptides.com/changes/pb-718.xml" rel="self" type="application/rss+xml" />
    <description>News, regulatory alerts, corrections and new guides about PB-718 on Grey Peptides, newest first.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 30 Oct 2026 12:00:00 +0000</lastBuildDate>
    <ttl>1440</ttl>
    <item>
      <title>Correction: Corrected: PB-718</title>
      <link>https://greypeptides.com/corrections/#c-q1018-pb718-class</link>
      <guid isPermaLink="false">greypeptides-changes-pb-718-corr-c-q1018-pb718-class</guid>
      <pubDate>Fri, 30 Oct 2026 12:00:00 +0000</pubDate>
      <category>Correction</category>
      <description>PB-718 is a long-acting dual agonist of the GLP-1 and glucagon receptors, developed for obesity and MASH; a US phase 1 and a Chinese phase 1b/2a are complete and unpublished.</description>
    </item>
  </channel>
</rss>
